| 6.58 0.34 (5.45%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.16 | 1-year : | 9.53 |
| Resists | First : | 6.98 | Second : | 8.16 |
| Pivot price | 6  |
|||
| Supports | First : | 5.42 | Second : | 4.44 |
| MAs | MA(5) : | 6.23 |
MA(20) : | 6.07 |
| MA(100) : | 3.24 |
MA(250) : | 7.29 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 88.5 |
D(3) : | 81.7 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 35 | Low : | 0.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ASBP ] has closed Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.66 - 6.68 | 6.68 - 6.71 |
| Low: | 6.14 - 6.17 | 6.17 - 6.2 |
| Close: | 6.52 - 6.58 | 6.58 - 6.62 |
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Mon, 20 Jul 2026
Aspire Bi clarifies public warrant terms after two reverse stock splits; exercise price now $13,800 - TradingView
Sat, 18 Jul 2026
LCID, ASBP, WLDS Stocks Hit 52-Week Lows: What Drove The Selloff? - Stocktwits
Sun, 12 Jul 2026
Aspire Biopharma Holdings Inc (ASBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sat, 04 Jul 2026
Price to book forward of Aspire Biopharma Holdings, Inc. – NASDAQ:ASBP - TradingView
Wed, 24 Jun 2026
Aspire Biopharma puts 50 mg caffeine stick packs on Amazon - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 1.22e+006 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 124 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 758.7 % |
| Return on Equity (ttm) | -74.7 % |
| Qtrly Rev. Growth | 34550 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 37533.3 |
| Qtrly Earnings Growth | -7.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.04 |
| Dividend | 0 |
| Forward Dividend | 101410 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|